Heart failure following a heart attack is a leading cause of death in the Western World. After a heart attack, cells in the heart die and the natural scaffolding that surrounds them, the extracellular matrix (ECM), is degraded and eliminated.
The heart has a very limited regenerative capacity and the area damaged by a heart attack is eventually replaced by scar tissue. The heart can then go through a downward progression in which it gradually loses the ability to function and effectively pump the amount of blood the body needs. This progression often leads to heart failure (HF).
Recent reports demonstrate that after a heart attack (or acute myocardial infarction (AMI)), 30% to 45% of patients will progress to heart failure (HF). The estimated direct and indirect healthcare expenditures for patients with this condition nears $26 billion annually in the US.
Currently, no products are available to specifically address the problem of the progression to heart failure after a heart attack. However, heart failure may be prevented if the damaged heart tissue can be repaired or regenerated. There is a need to bridge the gap in care between the heart attack and late-stage heart failure.
Ventrix is focused on delivering products for cardiac repair for heart attack patients who currently have very limited treatment options. A scaffold solution offers cardiac repair and regeneration that can prevent the progression toward heart failure and offer patients a longer and better quality of life.
Ventrix has developed a product, VentriGel, that is designed to replace and mimic native cardiac ECM. By replacing native cardiac ECM with VentriGelTM, the environment within the heart becomes ideal for the repair of the heart.